نتایج جستجو برای: rilpivirine

تعداد نتایج: 396  

2016
Kristof Theys Kristel Van Laethem Perpetua Gomes Guy Baele Andrea-Clemencia Pineda-Peña Anne-Mieke Vandamme Ricardo J. Camacho Ana B. Abecasis

OBJECTIVE The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of genotypic RPV resistance in treatment-naive patients outside clinical trials is poorly defined. STUDY DESIGN This retrospective observational study of clinical data from Belgium...

2015
Jason Brunetta Santiago Moreno Guillén Andrea Antinori Patrick Yeni Barbara Wade Margaret Johnson Peter Shalit Ramin Ebrahimi Bethsheba Johnson Ivan Walker Shampa De-Oertel

BACKGROUND Patient-reported outcomes (PROs) can provide important information about treatment tolerability in HIV-1-infected patients. OBJECTIVE The aim of this study was to evaluate PROs following switching from a boosted protease inhibitor-based regimen to the single-tablet regimen (STR) of rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) in the 48-week open-label Switc...

Journal: :International Journal of Pharmaceutical Sciences and Drug Research 2018

2017
Delphine Sculier Angèle Gayet-Ageron Manuel Battegay Matthias Cavassini Jan Fehr Cedric Hirzel Patrick Schmid Enos Bernasconi Alexandra Calmy

BACKGROUND Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the Swiss HIV Cohort Study and to assess its effec...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید